Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Alert Sacituzumab Govitecan Gains First-Line TNBC Indications Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 inhibitor ...
Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...
SHAREit is a popular application that allows you to easily transfer photos, videos, and files between iPhone, Android, and a Windows PC or Mac without an Internet connection. 2] Using Hotspot. The ...
If you don't use your credit card, your issuer may consider your account inactive and close it. However, a closed credit card account can negatively impact your credit score, by increasing your credit ...
ASCO 2026 Pivotal Updates in Metastatic Breast Cancer From ASCO 2026 Updates in metastatic breast cancer from ASCO 2026 include PANKU-Breast02 on iza-bren for TNBC, VIKTORIA-1 gedatolisib triplet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results